Now in its ninth year, the inVentiv Health Consulting Dealmakers' Intentions Study is the only forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries. While there are many quality sources of information that look historically at past deal trends, this survey offers a prospective view of the partnering and licensing landscape for the year ahead.
With insights gathered from dealmakers on the buy and sell side across the US, Europe and Asia, Dealmakers' Intentions presents conclusions that are crucial for C-suite executives, as well as executives responsible for dealmaking strategy and the business development function.
A summary of the study results was released during our Super Session at the BIO International Convention on June 20th. Download the white paper here. You can also listen to our inVentiv Health Podcast interview with co-author Sachin Purwar here
However, the results of this study are much more impactful and applicable to any company's business situation when they are delivered in person.
Request that an inVentiv Health Consulting team member present the full survey results to your organization and discuss its implications for your business.
Results from prior Dealmakers' Intentions studies can be found in our Landmark Studies section.